RPL3

Across TCGA pan-cancer cohorts, RPL3 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated RPL3 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RPL3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPL3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where RPL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	1.000	0.886	.001	28	view →
CCRCC	DFS	Tertile	III,IV	0.395	0.743	.004	27	view →
PDAC	OS	Tertile	II,III,IV	0.726	0.927	.012	26	view →
UCEC	OS	Median	II,III,IV	1.000	0.628	.013	10	view →
LSCC	DFS	Quartile	II,III,IV	0.943	0.518	.008	10	view →
OV	DFS	Median	All	0.678	0.923	.037	8	view →
GBM	DFS	Quartile	All	0.643	0.868	.004	5	view →
LUAD	OS	Quartile	II,III,IV	0.261	0.871	.004	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RPL3–HNSC (DFS)

Open the HNSC breakdown →